Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease.
OBJECTIVE
To describe the use of fluocinolone acetonide implants (Retisert) in Vogt-Koyanagi-Harada disease (VKH).


METHODS
Interventional case series.


METHODS
Retrospective review of medical records.


RESULTS
Two patients with VKH requiring high-dose systemic corticosteroid therapy to control their inflammation and bilateral serous retinal detachments received bilateral fluocinolone acetonide implants. Upon tapering of systemic corticosteroids, one patient had recurrent serous retinal detachments and the other patient's anterior chamber and vitreous inflammation returned.


CONCLUSIONS
The authors' experience with fluocinolone acetonide implants in VKH has been mixed with an inability to fully taper off of systemic corticosteroids.
Khalifa
Yousuf
Y
F.I. Proctor Foundation, University of California, San Francisco, California 94143-0412, USA.
Loh
Allison R
AR
Acharya
Nisha R
NR
D000284:Administration, Oral; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004343:Drug Implants; D004359:Drug Therapy, Combination; D005260:Female; D005446:Fluocinolone Acetonide / Q000008:administration & dosage*; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D012163:Retinal Detachment / Q000150:complications / Q000188:drug therapy; D012189:Retrospective Studies; D016896:Treatment Outcome; D014607:Uveomeningoencephalitic Syndrome / Q000150:complications / Q000188:drug therapy*; D014822:Vitreous Body; D055815:Young Adult
D004343:Drug Implants; D005938:Glucocorticoids; D005446:Fluocinolone Acetonide; D011241:Prednisone